Aquila Optimization Based Artificial Pancreas (AP) for Control of BG Level in TIDM Patient

The following article illustrates the conceptual framework of Aquila Optimization-PID (AO-PID) controller for managing the recommended insulin dosages to Interaction in Type-I Diabetes Mellitus (TIDM) patients using an AP in order to control blood glucose (BG) levels. Using the Aquila Optimization Algorithm (AOA), which regulates the suggested patient model's controller gains are used to enhance BG control. The purpose of this typical AO controller is to enhance patient robustness and effectiveness. Glycemic management is hampered by inconsistencies within the patient model. The nonlinear behavior of patient models is efficiently managed by employing an AP-based AO, which also keeps BG levels within the acceptable glycemic range (70–120 mg/dl). The accuracy, consistency, robustness, noise reduction, and enhanced capacity to manage uncertainty are assessed by using the recommended patient role models employing AO-PID. The explanations behind the recommended approach's better control capability are shown through a comparison of the outcomes of several control techniques.